Determination of the discriminant score of intestinal microbiota as a biomarker of disease activity in patients with ulcerative colitis

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Fukuda, Katsuyuki ^a   Fujita, Yoshiyuki ^a  

^a ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

Author keywords

Canonical discriminant function coefficient; Discriminant score; Intestinal microbiota; Operational taxonomic unit; Terminal restriction fragment length polymorphism; Ulcerative colitis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CONSANGUINITY; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DISEASE ACTIVITY; FEMALE; HUMAN; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; PHYLOGENETIC TREE; RELATIVE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TERMINAL RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ULCERATIVE COLITIS; CASE CONTROL STUDY; CHILD; CLINICAL TRIAL; CLUSTER ANALYSIS; COLITIS, ULCERATIVE; FECES; GENETICS; INFLAMMATION; INTESTINE; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CLUSTER ANALYSIS; COLITIS, ULCERATIVE; DISCRIMINANT ANALYSIS; FECES; FEMALE; HUMANS; INFLAMMATION; INTESTINES; MALE; MICROBIOTA; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84899493529     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-49     Document Type: Article

References (41)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002, 347:417-429. 10.1056/NEJMra020831, 12167685.
2. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009, 136:65-80. 10.1053/j.gastro.2008.10.080, 2892787, 19026645.
3. Uronis JM, Arthur JC, Temitope KT. Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis 2011, 17:289-297. 10.1002/ibd.21366, 2953593, 20564535.
4. Xavier R, Podolsky DK. Unraveling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434. 10.1038/nature06005, 17653185.
5. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007, 117:514-521. 10.1172/JCI30587, 1804356, 17332878.
6. Sartor RB. Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis and experimental intestinal inflammation. Inflammatory Bowel Disease 1999, 153-158. Baltimore: Williams & Wilkins, Kirsner JB, 5.
7. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003, 124:521-536. 10.1053/gast.2003.50045, 12557156.
8. Hu S, Wang Y, Lichtenstein L, Tao Y, Musch MW, Jabri B, Antonopoulos D, Claud EC, Chang EB. Regional differences in colonic mucosa-associated microbiota determine the physiological expression of host heat shock proteins. Am J Physiol Gastrointest Liver Physiol 2010, 299:G1266-G1275. 10.1152/ajpgi.00357.2010, 3006241, 20864653.
9. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut 2001, 48:132-135. 10.1136/gut.48.1.132, 1728175, 11115835.
10. Krishnan A, Korzenik JR. Inflammatory bowel disease and environmental influences. Gastroenterol Clin North Am 2002, 31:21-39. 10.1016/S0889-8553(01)00003-6, 12122733.
11. Sartor RB. Microbial influences in inflammatory bowel disease: role in pathogenesis and clinical implications. Kirsner's Inflammatory Bowel Diseases 2004, 138-162. Philadelphia: WB Saunders.
12. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002, 122:44-54. 10.1053/gast.2002.30294, 11781279.
13. Baumgar DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369:1627-1640. 10.1016/S0140-6736(07)60750-8, 17499605.
14. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003, 52:79-83. 10.1136/gut.52.1.79, 1773498, 12477765.
15. Buchler G, Wos-Oxley ML, Smoczek A, Zschemisch NH, Neumann D, Pieper DH, Hedrich HJ, Bleich A. Strain-specific colitis susceptibility in IL10-deficient mice depends on complex gut microbiota-host interactions. Inflamm Bowel Dis 2012, 18:943-954. 10.1002/ibd.21895, 22238116.
16. Cummings JH, Macfarlane GT. Colonic microflora: nutrition and health. Nutrition 1997, 13:476-478. 10.1016/S0899-9007(97)00114-7, 9225346.
17. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009, 15:1183-1189. 10.1002/ibd.20903, 19235886.
18. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004, 126:1620-1633. 10.1053/j.gastro.2004.03.024, 15168372.
19. Kanauchi O, Mitsuyama K, Araki Y, Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Des 2003, 9:333-346. 10.2174/1381612033391883, 12570821.
20. Tsuda Y, Yoshimatsu Y, Aoki H, Nakamura K, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol 2007, 42:1306-1311. 10.1080/00365520701396091, 17852859.
21. Furrie E, Macfarians S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA, Macfarlane GT. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomized controlled pilot trial. Gut 2005, 54:242-249. 10.1136/gut.2004.044834, 1774839, 15647189.
22. Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol 2005, 21:44-50.
23. Nishikawa J, Kudo T, Sakata S, Benno Y, Sugiyama T. Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis. Scand J Gastroenterol 2009, 44:180-186. 10.1080/00365520802433231, 18825588.
24. Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, Vandamme P, Vermeire S. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011, 60:631-637. 10.1136/gut.2010.223263, 21209126.
25. Brant SR. (Editorial). Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflamm Bowel Dis 2011, 17:1-5. 10.1002/ibd.21385, 20629102.
26. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Genetics Consortium NIDDKIBD, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 40:955-962. 10.1038/ng.175, 2574810, 18587394.
27. Orholm M, Munkholm P, Langholz E, Nielsen OH, Sørensen TI, Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991, 324:84-88. 10.1056/NEJM199101103240203, 1984188.
28. McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, Lagacé C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D'Amato M, Halfvarson J, Hibberd ML, Lördal M, Padyukov L, Andriulli A, Colombo E, Latiano A, Palmieri O, Bernard EJ, Deslandres C, Hommes DW, de Jong DJ, Stokkers PC, Weersma RK, et al. Genome-wide association multiple ulcerative colitis susceptibility loci. Nat Genet 2010, 42:332-337. 10.1038/ng.549, 3087600, 20228799.
29. Liu WT, Marsh TL, Cheng H, Forney LJ. Characterization of microbial diversity by determining terminal restriction fragment length polymorphisms of genes encoding 16S rRNA. Appl Environ Microbiol 1997, 63:4516-4522. 168770, 9361437.
30. Li F, Hullara M, Lampe J. Optimization of terminal restriction fragment polymorphism (TRFLP) analysis of human gut microbiota. J Microbiol Methods 2007, 68:303-311. 10.1016/j.mimet.2006.09.006, 1853299, 17069911.
31. Andoh A, Sakata S, Koizumi Y, Mitsuyama K, Fujiyama Y, Benno Y. Terminal restriction fragment length polymorphism analysis of the diversity of faecal microbiota in patients with ulcerative colitis. Inflamm Bowel Dis 2007, 13:955-962. 10.1002/ibd.20151, 17455205.
32. Sakamoto M, Hayashi H, Benno Y. Terminal restriction fragment length polymorphism analysis for human faecal microbiota and its application for analysis of complex bifidobacterial communities. Microbiol Immunol 2003, 47:133-142. 10.1111/j.1348-0421.2003.tb02796.x, 12680716.
33. Lichtiger S, Present DH, Kornbluth A. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841-1845. 10.1056/NEJM199406303302601, 8196726.
34. Nagashima K, Hisada T, Sato M, Mochizuki J. Application of new primer-enzyme combinations to terminal restriction fragment length polymorphism profiling of bacteria populations in human feces. Appl Environ Microbiol 2003, 69:1251-1262. 10.1128/AEM.69.2.1251-1262.2003, 143637, 12571054.
35. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012, 36:503-516. 10.1111/j.1365-2036.2012.05220.x, 22827693.
36. Matsuda H, Fujiyama Y, Andoh A, Ushijima T, Kajinami T, Bamba T. Characterization antibody response against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol 2000, 15:61-68. 10.1046/j.1440-1746.2000.02045.x, 10719749.
37. Lucke K, Miehlke S, Jacobs E, Schuppler M. Prevalence of bacteroides and provetella spp. in ulcerative colitis. J Med Microbiol 2006, 55:617-624. 10.1099/jmm.0.46198-0, 16585651.
38. Burgmann H, Pesaro M, Widmer F, Zeyer J. A strategy for optimizing quality and quantity of DNA extracted from soil. J Microbiol Methods 2001, 45:7-20. 10.1016/S0167-7012(01)00213-5, 11295193.
39. Marteau P, Lepage P, Mangin I, Suau A, Doré J, Pochart P, Seksik P. Review Article: gut flora and inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20(supple 4):18-23.
40. Lepage P, Seksik P, Sutren M, de la Cochetière MF, Jian R, Marteau P, Doré J. Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm Bowel Dis 2005, 11:473-480. 10.1097/01.MIB.0000159662.62651.06, 15867587.
41. Kojima A, Nakano K, Wada K, Takahashi H, Katayama K, Yoneda M, Higurashi T, Nomura R, Hokamura K, Muranaka Y, Matsuhashi N, Umemura K, Kamisaki Y, Nakajima A, Ooshima T. Infection of specific of Streptococcus mutans, oral bacteria, confers a risk of ulcerative colitis. Sci Rep 2012, 2(332):1-11.